ASND Ascendis Pharma A/S
- 132.020
- -1.440-1.08%
Ascendis Pharma A/S News
Ascendis Pharma Announces 2-Year Results From A Post-hoc Analysis Of Their Phase 3 Pathway Trial Demonstrating Sustained Improvements In Renal Function In Adults With Chronic Hypoparathyroidism Treated With TransCon PTH
Ascendis Pharma A/S (NASDAQ:ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function
Ascendis Pharma A/S Clinical And Quality-Of-Life Data For TransCon PTH-Treated Adults With Chronic Hypoparathyroidism To Be Presented At ECE 2024
Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism wi
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts started the week off on a positive note, rising 0.42% to 1,380.39 on the S&P Europe Select ADR Index. From continental Europe, the ga
Ascendis Pharma Is Maintained at Overweight by JP Morgan
Ascendis Pharma Is Maintained at Overweight by JP Morgan
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower
European equities traded in the US as American depositary receipts were trending modestly higher Friday morning, rising 0.42% to 1,371.48 on the S&P Europe Select ADR Index. Despite the gain, the inde
Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald
Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Corp.: Reiterates Ascendis Pharma (ASND.US) rating and adjusted from an increase to an increase in holdings rating, with a target price of $173.00.
Cantor Fitzgerald Corp.: Reiterates Ascendis Pharma (ASND.US) rating and adjusted from an increase to an increase in holdings rating, with a target price of $173.00.
Ascendis Pharma Q1 Net Loss Widens, Revenue Rises
Ascendis Pharma (ASND) reported a Q1 net loss late Thursday of 2.30 euros ($2.47) per diluted share, compared with a loss of 1.98 euros a year earlier. Analysts polled by Capital IQ expected a per-sha
Ascendis Pharma Q1 Sales €95.894M Beat €79.492M Estimate
Ascendis Pharma Q1 Sales €95.894M Beat €79.492M Estimate
Ascendis Pharma Reports Q1 Results
Ascendis Pharma: As of March 31Had Cash, Cash Equivalents, Marketable Securities Totaling EUR320 >ASND
Ascendis Pharma: As of March 31Had Cash, Cash Equivalents, Marketable Securities Totaling EUR320 >ASND
Earnings Flash (ASND) ASCENDIS PHARMA Reports Q1 Revenue EUR95.9M
04:01 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (ASND) ASCENDIS PHARMA Reports Q1 Revenue EUR95.9M
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%
European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.5% to 1,380.32 on the S&P Europe Select ADR Index. With the gain, the index is set to c
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
COPENHAGEN, Denmark, April 25, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will report first quarter 2024 financial results and provide a business update on Thursday, May 2, 2024,
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading
European equities traded in the US as American depositary receipts were trending modestly higher Thursday morning, rising 0.24% to 1,364.10 on the S&P Europe Select ADR Index. From continental Europe,
Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism
Ascendis Pharma (ASND) said Wednesday that the UK's Medicines and Healthcare Products Regulatory Agency has granted marketing authorization for Yorvipath as a parathyroid hormone, or PTH, replacement
MHRA Approves YORVIPATH In Great Britain For Adults With Chronic Hypoparathyroidism
MHRA Approves YORVIPATH In Great Britain For Adults With Chronic Hypoparathyroidism
Morgan Stanley Maintains Equal-Weight on Ascendis Pharma, Maintains $116 Price Target
Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma with a Equal-Weight and maintains $116 price target.
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.46% to 1,330.20 on the S&P Europe Select ADR Index. Despite the gain, the index remains
$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 17.87% on an annualized basis producing an average annual return of 30.26%. Currently, Ascendis Pharma has a market
Analysis
Price Target
No Data
